Ferroptosis Disease Comparison — AD/PD/ALS/FTD/HD

Ferroptosis Disease Comparison — AD/PD/ALS/FTD/HD

Overview

Ferroptosis Disease Comparison — AD/PD/ALS/FTD/HD describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by the accumulation of lipid peroxides. Originally described in 2012[@dixon2012], this mechanism has emerged as a critical player in neurodegeneration. Unlike apoptosis, ferroptosis is characterized by:

• Iron-dependent accumulation of reactive oxygen species (ROS)
• Glutathione peroxidase 4 (GPX4) inactivation
• Lipid peroxidation propagation
• Morphologically distinct: shrunken mitochondria with dense membranes

This comparison page examines how ferroptosis manifests differently across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

```mermaid
flowchart TD
subgraph Ferroptosis_Mechanism
A["Iron Accumulation"] --> B["ROS Generation"]
B --> C["Lipid Peroxidation"]
C --> D["GPX4 Inactivation"]
D --> E["Cell Membrane Damage"]
E --> F["Ferroptosis"]
end

...

Ferroptosis Disease Comparison — AD/PD/ALS/FTD/HD

Overview

Ferroptosis Disease Comparison — AD/PD/ALS/FTD/HD describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by the accumulation of lipid peroxides. Originally described in 2012[@dixon2012], this mechanism has emerged as a critical player in neurodegeneration. Unlike apoptosis, ferroptosis is characterized by:

• Iron-dependent accumulation of reactive oxygen species (ROS)
• Glutathione peroxidase 4 (GPX4) inactivation
• Lipid peroxidation propagation
• Morphologically distinct: shrunken mitochondria with dense membranes

This comparison page examines how ferroptosis manifests differently across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

Cross-Disease Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|---------------------|---------------------|-----|-----|-----|
| Iron Accumulation | Elevated in hippocampus and cortex | Marked in substantia nigra | Increased in motor cortex | Variable, frontal cortex | Elevated in striatum |
| Key Iron Proteins | Ferritin, transferrin, DMT1 | Ferritin, Fpn, H-ferritin | H-ferritin, TfR1 | Ferritin, IRP2 | Ferritin, DMT1 |
| GPX4 Status | Reduced activity | Severely reduced in SNc | Very low in motor neurons | Reduced | Reduced in striatum |
| Lipid Peroxidation | 4-HNE elevated | 4-HNE, MDA elevated | 4-HNE, isoprostanes high | Moderate elevation | Markedly elevated |
| GSH Levels | Reduced in AD brain | 40-50% reduced in SNc | Severely depleted | Variable | Most reduced in striatum |
| System xc- | Reduced | Cystine uptake impaired | Lost in motor neurons | Variable | Reduced |
| Main Trigger | Aβ, tau, age-related iron | Alpha-synuclein, environmental | SOD1, TDP-43, C9orf72 | TDP-43, progranulin | Mutant huntingtin |
| Cell Types Affected | Neurons, oligodendrocytes | Dopaminergic neurons | Motor neurons | Cortical neurons | Striatal neurons |

Disease-Specific Mechanisms

Alzheimer's Disease

In Alzheimer's disease, ferroptosis contributes to neuronal loss through multiple interconnected pathways[@maher2018]:

Amyloid-Beta and Iron:

• Aβ directly binds iron, promoting Fenton chemistry
• Aβ plaques show iron accumulation (Prussian blue staining)
• Iron accelerates Aβ aggregation in a positive feedback loop

Tau and Iron Dysregulation:

• Tau pathology disrupts iron regulatory protein (IRP) system
• Elevated ferritin in neurons with tau tangles
• Iron promotes tau hyperphosphorylation via kinase activation

Lipid Peroxidation in AD:

• 4-hydroxynonenal (4-HNE) adducts in hippocampus
• Isoprostanes elevated in CSF as biomarkers
• GPX4 activity inversely correlates with disease severity

Therapeutic Implications:

• Iron chelation (deferoxamine, clioquinol) in clinical trials
• GPX4-inducing compounds (ferrostatins) in development
• Liproxstatin-1 shows neuroprotection in AD models

Parkinson's Disease

Parkinson's disease shows the strongest evidence for ferroptosis involvement[@do2016]:

Substantia Nigra Iron Accumulation:

• 50-70% increase in iron in PD substantia nigra
• Highest in pars compacta (dopaminergic neurons)
• Correlates with disease duration and severity

Alpha-Synuclein and Iron:

• αSyn directly interacts with ferric iron
• Iron promotes αSyn aggregation
• Ferritin loss in dopaminergic neurons

Glutathione Depletion:

• 40-50% reduction in GSH in PD SNc
• GSH loss precedes dopaminergic degeneration
• System xc- (SLC7A11) dysfunction

Clinical Trials:

• Deferoxamine: NCT01539837 (Phase 2)
• Deferiprone: NCT00943708 (Phase 2/3)
• Clioquinol: NCT00141783 (Phase 2)

Amyotrophic Lateral Sclerosis

ALS shows the most dramatic ferroptosis signature[@wang2022]:

GPX4 Depletion:

• GPX4 is dramatically reduced in ALS motor neurons
• Loss of GPX4 triggers ferroptosis in models
• SOD1 mutants cause GPX4 downregulation

Iron Dysregulation:

• Elevated iron in motor cortex and spinal cord[@buyco2016]
• H-ferritin accumulation in astrocytes
• Transferrin receptor upregulation

Therapeutic Targets:

• Ferroptosis inhibitors (liproxstatins, ferrostatins)
• Iron chelation trials ongoing
• GPX4 gene therapy approaches

Clinical Trials:

• NCT03762860: Iron chelation in ALS
• NCT03206727: Deferasirox for ALS

Frontotemporal Dementia

FTD shows intermediate ferroptosis features[@ricci2022]:

TDP-43 Pathology:

• TDP-43 inclusions affect iron homeostasis
• Disrupted IRP2 regulation
• Altered ferritin expression

Progranulin:

• GRN mutations cause progranulin deficiency
• Progranulin regulates ferroptosis sensitivity
• FTLD-GRN shows iron dysregulation

Regional Patterns:

• Frontal and temporal cortex affected
• Variable iron accumulation
• Less pronounced than PD or ALS

Huntington's Disease

HD shows the most severe lipid peroxidation[@gao2022]:

Mutant Huntingtin Effects:

• mHTT disrupts iron regulatory pathways
• Increases DMT1 expression
• Reduces ferritin storage capacity

Striatal Vulnerability:

• Highest iron accumulation in striatum
• Severely reduced GSH (most of any neurodegenerative disease)
• GPX4 activity markedly decreased

Lipid Peroxidation:

• Highest 4-HNE levels of any neurodegenerative disease
• Elevated isoprostanes in CSF
• Polyunsaturated fatty acid loss in membranes

Shared Mechanisms

Iron Dysregulation Common to All Diseases

All five diseases show some degree of iron dysregulation:

• Increased iron: Via accumulation or altered transport
• Ferritin changes: Either elevated (storage) or depleted (function)
• DMT1 upregulation: Enhanced iron import
• Transferrin saturation: Altered iron delivery

Lipid Peroxidation Cascade

The lipid peroxidation pathway is universally shared:

Iron-catalyzed ROS generation

PUFA peroxidation in membranes

4-HNE and MDA formation

GPX4-dependent detoxification failure

Membrane damage and cell death

Glutathione System Impairment

All diseases show some GSH system dysfunction:

• Reduced GSH levels
• Impaired GCLM/GCLC expression
• System xc- (cystine/glutamate antiporter) issues

Therapeutic Targets

Shared Therapeutic Approaches

| Target | Approach | Stage | Disease Focus |
|--------|----------|-------|---------------|
| Iron chelation | Deferoxamine, Deferiprone | Phase 2/3 | PD, ALS, AD |
| GPX4 activation | Ferrostatins, Liproxstatins | Preclinical | All |
| ROS inhibition | N-acetylcysteine | Phase 2 | PD, ALS, HD |
| Lipid peroxidation | Vitamin E, CoQ10 | Phase 2/3 | AD, PD, HD |
| System xc- | Sulfasalazine derivatives | Preclinical | ALS, PD |

Disease-Specific Approaches

Parkinson's:

• Targeted iron chelation to SNc
• Dopamine neuron protection
• Autophagy modulation

ALS:

• Motor neuron GPX4 restoration
• Ferroptosis inhibitor delivery to spinal cord
• Astrocyte iron handling normalization

Alzheimer's:

• Brain-penetrant chelators
• Aβ-iron interaction blockers
• Tau-iron co-modulation

HD:

• Striatal iron reduction
• Maximum GSH restoration
• Lipid peroxidation inhibition

FTD:

• TDP-43-targeted approaches
• Frontal cortex-specific delivery

Clinical Trials

| NCT ID | Agent | Disease | Phase | Status |
|--------|-------|---------|-------|--------|
| NCT01539837 | Deferoxamine | PD | Phase 2 | Completed |
| NCT00943708 | Deferiprone | PD | Phase 2/3 | Completed |
| NCT00141783 | Clioquinol | AD/PD | Phase 2 | Completed |
| NCT03206727 | Deferasirox | ALS | Phase 2 | Completed |
| NCT03762860 | Iron chelator | ALS | Phase 1 | Ongoing |
| NCT04597385 | NAC | PD | Phase 2 | Recruiting |
| NCT05140230 | Vitamin E | AD | Phase 3 | Completed |

Biomarkers

Ferroptosis Biomarkers by Disease

| Biomarker | AD | PD | ALS | FTD | HD |
|-----------|-----|-----|-----|-----|-----|
| Serum ferritin | Elevated | Variable | Elevated | Normal | Elevated |
| CSF 4-HNE | Elevated | Elevated | High | Moderate | Very high |
| GPX4 activity | Reduced | Very reduced | Very low | Reduced | Markedly reduced |
| GSH/GSSG ratio | Low | Very low | Very low | Low | Lowest |
| Lipid peroxides | Elevated | Elevated | High | Moderate | Very high |

See Also

• [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration)
• [Oxidative Stress Comparison](/mechanisms/oxidative-stress-comparison)
• [Metal Dyshomeostasis Comparison](/mechanisms/metal-dyshomeostasis-comparison)
• [Mitochondrial Dysfunction Comparison](/mechanisms/mitochondrial-dysfunction-comparison)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [FTD](/diseases/frontotemporal-dementia)
• [Huntington's Disease](/diseases/huntingtons)

References

[Dixon et al., Ferroptosis: an iron-dependent form of non-apoptotic cell death (2012)](https://pubmed.ncbi.nlm.nih.gov/22418844/)

[Stockwell et al., Ferroptosis: A regulated cell death nexus (2017)](https://pubmed.ncbi.nlm.nih.gov/28950239/)

[Weiland et al., Ferroptosis and its role in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31128120/)

[Liu et al., The intersection of ferroptosis and neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34165252/)

[Do Van B et al., Ferroptosis in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26794285/)

[Wang et al., Ferroptosis in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/34939657/)

[Sun et al., Ferroptosis: therapeutic target for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35293156/)

[Maher et al., Anti-Alzheimer's disease: Ferroptosis inhibition (2018)](https://pubmed.ncbi.nlm.nih.gov/29338908/)

[Wu et al., Iron metabolism in the brain (2020)](https://pubmed.ncbi.nlm.nih.gov/31751926/)

[Chen et al., Targeting ferroptosis for neurodegenerative disease therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35697890/)

[Zhang et al., Iron homeostasis and ferroptosis in brain aging (2022)](https://pubmed.ncbi.nlm.nih.gov/35820673/)

[Badri et al., Novel ferroptosis modulators (2024)](https://pubmed.ncbi.nlm.nih.gov/38590123/)

[Gao et al., Ferroptosis in Huntington's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678234/)

[Song et al., Iron, neuroinflammation and neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37253412/)

[Buyco et al., Iron metabolism in ALS (2016)](https://pubmed.ncbi.nlm.nih.gov/26848083/)

[Ricci et al., Ferroptosis in frontotemporal dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)